What does the future look like with the curren... - CLL Support
What does the future look like with the current BTK & BCL-2 inhibitors?
You need to be a member of this community to see this post.
Read more about...
9 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'
In just a short time, in many places, BTK inhibitors (BTKi) have largely replaced...
CLL survival times ARE improving, thanks to BTK and BCL-2 inhibitors
Many of us were shocked after our CLL/SLL diagnosis when we googled for survival times....
Can Venetoclax/Obinituzimab reduce the risk of additional somatic mutations? - Not necessarily. The BTK inhibitors are excellent at....
Below is a repost from CLLSLL@groups.io ( permission granted by Dr. Furman)
- I believe this...
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
From the New England Journal of Medicine 10th December 2023
"The CLL treatment landscape has...
YABTKi or Yet Another BTK inhibitor - the A to Z list of Bruton's Tyrosine Kinase Inhibitors for CLL following Ibrutinib's success
I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
Related Posts
2 Issues: Ibrutinib side effects + Ibrutinib plus Venetoclax Treatment- Clinical trial results & reviews of new treatments for CLL written in easy to understand terms
- Dr. John Allan - Chronic Lymphocytic Leukemia (CLL) Patients @Undetectable Measurable Residual Disease (MRD) after Ibrutinib Plus Venetoclax
- Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
Ibrutinib and Obinutuzumab with Venetoclax
